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 Introduction: Central diabetes insipidus (CDI), as a manifestation of acute myeloid leukemia, is rare, but has 
been noted in association with dysmegakaryopoiesis and chromosomes 3 abnormalities. Particularly in 
association with monosomy 7, the association is now considered to be more than fortuitous.  A distinct 
mechanism has not been defined for the etiology of CDI, however it has been suggested that different 
cytogenetics may act through different disease processes to manifest in this rarely seen phenomenon. Our 
case illustrates a case of CDI with chromosome 3 abnormalities, in a patient who developed acute 
myelocytic leukemia following treatment with Temodar for a pancreatic neuroendocrine tumor. 
 
conjugation with the requirement of DNA fracture and chromosome reassembly for the occurrence of normal 
hematopoiesis.  The majority of AML diagnoses occur de novo with secondary cases resulting from either transformation of 
pre-existing hematologic disorder or due to toxic exposure (chemotherapy, radiation, environmental toxins, etc).  Often 
times, these secondary cases are more refractory to therapy.  The World Health Organization classifies AML as a blast count 
of 20% or greater, further characterizing the disease by genetic and morphologic features categorizing it in one of the 
following four categories: AML with recurrent genetic abnormalities (category I), AML with multilineage dyplasia (category 
II), AML developing secondary to therapeutic intervention (category III), and AML not otherwise categorized (category IV).  
Our current case is representative of category III, and is most likely related to protracted use of Temodar.   
 AML most commonly presents with fatigue, however, rarely, central diabetes insipidus may manifest associated with 
certain cytogenetic abnormalities of chromosome 3 and monosomy 7.  These cases are associated with poor prognosis as 
they are often refractory to chemotherapy.  Two distinct mechanisms have been proposed to explain this uncommon 
presentation of AML.  Cases of AML associated with dysmegakaryopoiesis and thrombocytosis along with certain cytogenetic 
abnormalities suggest a platelet mediated induction of CDI.  Approximately 90% of circulating antidiuretic hormone is 
associated with platelets, and dysmegakaryopoiesis, along with elevated platelet count could be one possible explanation of 
this disease manifestation.  This is thought to be secondary to inappropriate activation of the EVI-1 transcription factor.  
Other cases have reported imaging changes in the neurohypophysis suggesting that leukemic infiltration causing pituitary 
dysfunction represents another possible mechanism.  One case described persistence of CDI after remission of AML further 
enforcing that disruption of the posterior pituitary resulted in CDI.  Our case was without MRI imaging abnormality, however 
abnormalities of chromosome 3, dysmegakaryopoiesis, and thrombocytosis were present.  Review of these cases suggest 
that rather than any single process, at least two separate mechanisms exist which lead to the development of CDI in AML. 
 In conclusion, regardless of mechanism, presence of CDI is a poor prognostic indicator when present in AML.  While 
exact mechanisms of this presentation are not yet completely defined it is likely that different cytogenetic abnormalities 
result different processes to manifest CDI. Given the dismal outcome of patients presenting with CDI and AML a need for 
early initiation of aggressive therapeutic interventions would be suggested. 
Case: 35-year-old female, with past medical history of pancreatic neuroendocrine tumor (treated with a 
protracted course of Temodar), diabetes mellitus, hypertension, hyperlipidemia, and hypothyroidism, 
presented with progressive shortness of breath, and productive cough with subsequent treatment with 
antibiotics for a possible community-acquired pneumonia. RSV was eventually defined after CT revealed 
ground glass opacities and bronchoscopy washings grew the virus.  Treatment was changed to ribavirin with 
resolution of RSV pneumonia.   Also, on admission, acute kidney injury was present, and urine output was 
noted to be persistently greater than 8 L per day. Central diabetes insipidus was suspected. MRI of the brain 
with special attention to the pituitary was without abnormality, and a water deprivation test was 
inconclusive likely due to acute kidney injury. The patient was also noted to have a persistent leukocytosis 
with immature cells present in peripheral blood.  A subsequent bone marrow examination revealed acute 
myelocytic leukemia, and cytogenetics on the bone marrow biopsy demonstrated inversion of 3 q and 
presence of 15% EV1 probe positivity.  This mutation has been associated with thrombocytosis and 
dysmegakaryopoiesis, which has led to the suggestion of a platelet-mediated mechanism of CDI.  The patient 
was started on induction chemotherapy with ARA C and Danourubicin, and subsequently she had notable 
improvement of her polyuria, along with resolution of hypernatremia, and acute kidney injury.  38% blasts on 
repeat bone marrow aspirate prompted re-induction with high dose Ara-C.  She is currently in remission after 
2 cycles of HIDAC and last bone marrow aspirate revealed normal cytogenetics with resolution of all features 
of diabetes insipidus.   
 
Discussion:  Acute Myelogenous Leukemia is a relatively rare cancer, however approximately 
10,000 new cases are diagnosed in the United States are  each year with incidence greatly 
increasing after age 65 probably related to failure of innate DNA repair mechanisms with aging, in 
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A B C 
Images A and B are sections from the patient’s pituitary MRI and are without abnormality.  
Image C is from the patients CT chest showing ground glass infiltrates 
